CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Compugen Ltd. - Ordinary Shares - CGEN CFD

1.5752
0.64%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0196
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-4.63)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.5652
Open 1.5752
1-Year Change 111.07%
Day's Range 1.5752 - 1.5852
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 1.5652 0.0200 1.29% 1.5452 1.5952 1.5352
Dec 16, 2024 1.5652 0.0100 0.64% 1.5552 1.6152 1.5552
Dec 13, 2024 1.5752 -0.0400 -2.48% 1.6152 1.6152 1.5352
Dec 12, 2024 1.5952 0.0400 2.57% 1.5552 1.6252 1.5452
Dec 11, 2024 1.5752 -0.0200 -1.25% 1.5952 1.6652 1.5752
Dec 10, 2024 1.6052 -0.0300 -1.83% 1.6352 1.6552 1.5852
Dec 9, 2024 1.6252 -0.0300 -1.81% 1.6552 1.6652 1.5852
Dec 6, 2024 1.6352 0.0500 3.15% 1.5852 1.6552 1.5552
Dec 5, 2024 1.5552 0.0100 0.65% 1.5452 1.5752 1.5252
Dec 4, 2024 1.5852 0.0700 4.62% 1.5152 1.6952 1.5152
Dec 3, 2024 1.5352 0.0700 4.78% 1.4652 1.5352 1.4652
Dec 2, 2024 1.4952 -0.0600 -3.86% 1.5552 1.5552 1.4852
Nov 29, 2024 1.5652 -0.0400 -2.49% 1.6052 1.6252 1.5452
Nov 27, 2024 1.5852 0.0400 2.59% 1.5452 1.6552 1.5252
Nov 26, 2024 1.5152 0.1100 7.83% 1.4052 1.5352 1.3552
Nov 25, 2024 1.4052 -0.0100 -0.71% 1.4152 1.4352 1.3652
Nov 22, 2024 1.3852 -0.0300 -2.12% 1.4152 1.4452 1.3552
Nov 21, 2024 1.4352 0.0500 3.61% 1.3852 1.5052 1.3852
Nov 20, 2024 1.4152 0.0000 0.00% 1.4152 1.4852 1.3852
Nov 19, 2024 1.4352 0.0200 1.41% 1.4152 1.4352 1.3852

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Compugen Ltd. Company profile

About Compugen Ltd. (USA)

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Compugen Ltd. (USA) revenues increased from $2M to $6M. Net loss increased 15% to $34.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development increase of 24% to $26.7M (expense), Interest Income decrease of 49% to $894K (income).

Equity composition

Ordinary Shares NIS.01 Par, 12/10 50M auth., 33,915,545 issd. Insiders own 11.33%. IPO: 8/11/00, 5M shares @ $10 by FleetBoston Robertson Stephens. FY'00 financials are reclassified.

Industry: Biotechnology & Medical Research (NEC)

26 הרוקמים
HOLON
5885849
IL

People also watch

BTC/USD

104,922.50 Price
-1.550% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

ETH/USD

3,884.58 Price
-1.330% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

US100

21,990.10 Price
0.000% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,637.23 Price
-0.340% 1D Chg, %
Long position overnight fee -0.0083%
Short position overnight fee 0.0001%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading